TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00497198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-196
Description: Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of MCI-196 Tablet
Description: Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
Study: NCT04417972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR7280
Description: treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: blank control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control
Study: NCT01202383

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Household-based water treatment with NADCC tablets
Description: Study participants will be supplied with tablets and encouraged to use them for treating their water daily
Study: NCT01410825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retrovirus-mediated gene transfer
Description: Two procedures: 1) Bone marrow harvest from the patient's posterior iliac crests or collection of peripheral blood stem cells via apheresis procedure. 2) One time infusion of patient's transduced bone marrow cells.
Study: NCT00955734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early motion
Description: One set of patients will begin wrist motion at 1 week after surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization
Description: This set of patients will be casted for 6 weeks after surgery.
Study: NCT04417972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control
Study: NCT01832103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7145
Study: NCT00957788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-001
Description: Comparison of different dosages of drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-001
Description: Comparison of different dosages of drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-001
Description: Comparison of different dosages of drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-001
Description: Comparison of different dosages of drug.
Study: NCT01830881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 800 mg oral ibuprofen 30-60 minutes prior to procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: 800 mg oral ibuprofen 30-60 minutes prior to procedure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Cherry syrup
Description: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: injection of 20 mL 1% lidocaine without epinephrine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: injection of 20 mL 1% lidocaine without epinephrine
Study: NCT02867969

Intervention type: OTHER
Group type: OTHER
Intervention: Motor training
Description: The motor training will comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
Study: NCT01619046

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GreenGene™ F and an approved recombinant Factor VIII product
Description: one 50 IU/kg, intra-venous infusion over 5 minutes, Infusion rate \< 10 mL/min

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GreenGene™ F
Description: intra-venous infusion, 30 ± 5 IU/kg infusions 3 times per week with dose escalation to 45 ± 5 IU/kg if appropriate, for 50 exposure days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GreenGene™ F
Description: intra-venous infusion,~On-demand safety and efficacy substudy:~minor bleed = 10-20 IU/kg moderate bleed = 15-30 IU/kg major bleed = 30-50 IU/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GreenGene™ F
Description: intra venous infusion,~Surgical substudy:~Minor surgery including tooth extraction = Post in fusion FVIII level of 60-100% of normal. A single bolus infusion (30-50 IU/kg) beginning within one hour of the operation. Optional additional dosing every 12 to 24 hours as needed to control bleeding.~Major surgery = Pre- and post infusion FVIII level 80-120% of normal. Preoperative bolus infusion: 40-60 IU/kg. Verified 100% activity prior to surgery. Maintenance bolus infusion (40-60 IU/kg) repeat infusions every 8 to 24 hours, depending on the desired level.
Study: NCT02038764

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose A
Description: Multiple SC Doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose B
Description: Multiple SC Doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose C
Description: Multiple SC Doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose D
Description: Multiple SC Doses
Study: NCT01989559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100:209-217(210M) Peptide Vaccine
Description: Given SC
Study: NCT03729570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePrEP
Description: Participants will have a baseline teleconsultation with a site study clinician who will be responsible for prescribing PrEP as indicated. They will be offered a 1-month check-in and telemedicine consultations at 3, 6, 9 and 12 months. Participants will complete home specimen collection for laboratory tests for each consultation. The virtual study visit consists of surveys, specimen collection, and a telemedicine consultation.
Study: NCT02794701

Intervention type: OTHER
Intervention: People with silicosis
Study: NCT00847782

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: 1 day
Study: NCT01989559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV 16 E7:12-20 Peptide Vaccine
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02811094

Intervention type: OTHER
Group type: OTHER
Intervention: polymerase chain reaction (PCR) technique of blood transcriptome analysis
Description: this study (LUMIER2 study) is to test the hypothesis that a test score or prognostic transcriptomic allows to discriminate clinically quiescent or patients who will not present a push of Systemic Lupus Erythematosus
Study: NCT01305096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Description: 6 weeks of yoga postures, once a week for 60 minutes in a group session with a yoga teacher.
Study: NCT01161693

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: TROOP® elevation pillow
Description: Maternal Comfort after CSE during elective Cesarean Section in relation to adequate height of Anesthetic Block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TROOP® elevation pillow
Description: designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TROOP® elevation pillow
Description: designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
Study: NCT04192630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CVisc50 OVD
Description: Bausch + Lomb CVisc50 Cohesive OVD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProVisc OVD
Description: ProVisc OVD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Cataract Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract Surgery
Description: Cataract Surgery
Study: NCT03653663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 20 mg
Description: Subjects are treated with 20 mg simvastatin for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Subjects are treated with placebo for 8 weeks
Study: NCT00204308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination tenofovir-emtricitabine
Description: Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor
Study: NCT01684995

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief physician advice
Description: Brief physician advice to quit smoking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief physician advice
Description: Brief physician advice to quit smoking

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Description: nicotine patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: nicotine patch

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individually Tailored Behavioral Skills training
Description: Individually tailored behavioral skills training for smoking cessation
Study: NCT03562455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VRSim 3.0
Description: VRSim 3.0 is a virtual reality training module.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Wheelchair Training
Description: A therapist will be used to train power wheelchair users.
Study: NCT02694484

Intervention type: OTHER
Group type: OTHER
Intervention: Blood and stool samples
Description: Blood sample at Day 1 and blood and stool sample at the next visit
Study: NCT02952573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493
Description: Once daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493
Description: Once daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Cycle 1 and 2: OD dosing on days 1-4, 9-12, and 17-20;Cycle 3: OD dosing on days 1, 8, 15, 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Cycle 1 and 2: OD dosing on days 1-4, 9-12, and 17-20;Cycle 3: OD dosing on days 1, 8, 15, 22
Study: NCT02571621

Intervention type: DEVICE
Intervention: Combitube
Description: Intubation with Combitube
Study: NCT00847782

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: 1 day

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: 1 day
Study: NCT01185509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Study: NCT00800306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Intravenous administration of Levosimendan 0,2 µg•kg-1•min-1 for 24 hrs followed by the addition of 35 ppm of inhaled nitric oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dobutamine
Description: Intravenous administration of dobutamine 5 µg•kg-1•min-1 for 36 hrs. At the end of the first 24 hrs drug infusion, inhaled nitric oxide at the concentration of 35 ppm will be added for further 12 hrs.
Study: NCT03268824

Intervention type: DEVICE
Intervention: Electroencephalogram (EEG)
Description: Intracerebral electroencephalogram (EEG) will be analysed to quantify the intensity of epileptic discharge (the epileptogenicity index) on each electrode contact (only for children with focal epilepsy).

Intervention type: DEVICE
Intervention: Diffusion Tensor imaging
Description: We will perform Diffusion Tensor imaging in order to relate tractography measures to seizure recordings. Loss of connectivity (or disconnections) will be determined with diffusion tractography for each brain region. Then we will correlate the degree of epileptogenicity with the number of disconnections.

Intervention type: DEVICE
Intervention: Diffusion Tensor imaging
Description: We will perform Diffusion Tensor imaging in order to relate tractography measures to seizure recordings. Loss of connectivity (or disconnections) will be determined with diffusion tractography for each brain region. Then we will correlate the degree of epileptogenicity with the number of disconnections.

Intervention type: OTHER
Intervention: Language assessment
Description: The language assessment will be adapted to the age of the child, with a predominant neuropsychological component.

Intervention type: OTHER
Intervention: Language assessment
Description: The language assessment will be adapted to the age of the child, with a predominant neuropsychological component.
Study: NCT00792376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac
Description: diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac
Description: diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
Study: NCT02247635

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyle and adherence
Description: Behavioral intervention to improve adherence to treatment and 1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake \<30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.~The model consists of monthly visits to the doctor, nutritionist and psychologist, for screening cardiometabolic risk factors, to know limitations on treatment adherence, to start intervention to evaluate reasons for success or failure, to evaluate and maintain motivation to adherence to diet, physical activity and medication and long-term care
Study: NCT03780803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home cardiac rehabilitation and respiratory rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home cardiac rehabilitation and respiratory rehabilitation
Study: NCT04583683

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Very low calorie diet with Fortimel (Nutricia) supplementation
Description: Patients will undergo a very low calorie diet

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metabolic Surgery
Description: Patients will undergo metabolic surgery
Study: NCT04205929

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin 600 mg (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
Study: NCT03102658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Administration of study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: Administration of study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: Administration of study drug
Study: NCT04116944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: The ecologically-valid resistance exercise training was designed according to World Health Organization and American College of Sports Medicine guidelines. The eight-week, twice-weekly intervention was designed to be performed at a moderate intensity. The resistance of each exercise was such that when participants could successfully complete 2 sets of 12 repetitions at a certain load, the resistance was increased incrementally up to 5% for the following session. Exercise sessions were scheduled with at least one day of rest between sessions. The eight exercises included the barbell squat, barbell bench press, hexagon bar deadlift, dumbbell shoulder lateral raise, barbell bent over rows, dumbbell lunges, dumbbell curls, and abdominal crunches.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: The ecologically-valid resistance exercise training was designed according to World Health Organization and American College of Sports Medicine guidelines. The eight-week, twice-weekly intervention was designed to be performed at a moderate intensity. The resistance of each exercise was such that when participants could successfully complete 2 sets of 12 repetitions at a certain load, the resistance was increased incrementally up to 5% for the following session. Exercise sessions were scheduled with at least one day of rest between sessions. The eight exercises included the barbell squat, barbell bench press, hexagon bar deadlift, dumbbell shoulder lateral raise, barbell bent over rows, dumbbell lunges, dumbbell curls, and abdominal crunches.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list
Description: Participants randomized to the delayed-start wait-list condition completed questionnaires once-weekly. The investigator sent a weekly email to the participant providing links to the questionnaires. Participants that completed the eight-week wait-list condition were offered the eight weeks of RET either immediately upon completion, or later at a time of their convenience while the trial was ongoing. Each participant randomized to the eight-week wait-list also completed two 30-minute bouts of seated quiet rest in an empty room at weeks one and eight.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list
Description: Participants randomized to the delayed-start wait-list condition completed questionnaires once-weekly. The investigator sent a weekly email to the participant providing links to the questionnaires. Participants that completed the eight-week wait-list condition were offered the eight weeks of RET either immediately upon completion, or later at a time of their convenience while the trial was ongoing. Each participant randomized to the eight-week wait-list also completed two 30-minute bouts of seated quiet rest in an empty room at weeks one and eight.
Study: NCT00547690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and Strengthening
Description: Acupuncture and strengthening

Intervention type: OTHER
Group type: OTHER
Intervention: Strengthening Alone
Description: Strengthening training program
Study: NCT03780803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home cardiac rehabilitation and respiratory rehabilitation
Study: NCT00655733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-004
Description: HMPL-004 1200 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1200 mg/d
Study: NCT01335217

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcutaneous Electrical Nerve Stimulator (TENS)
Description: External trigeminal nerve stimulation (TNS) as an adjunctive treatment for adults with major depressive disorder (MDD) co- occurring with posttraumatic stress disorder (PTSD) when added onto antidepressant medications
Study: NCT03560726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management
Description: Cognitive behavioral stress management is a well-established, practical intervention that combines elements of cognitive behavioral therapy with techniques designed to improve coping skills, social support, communication, and relaxation/mindfulness.
Study: NCT00312065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of reflective heat shield to thermistor probe
Study: NCT02946073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo